李婷;鄒秋萍;何紅平;王亭;黃豐;李艷平;
LI Ting;ZOU Qiu-ping;HE Hong-ping;WANG Ting;HUANG Feng;LI Yan-ping;School of Chinese Medicine, Yunnan University of Traditional Chinese Medicine;

• 1:云南中醫藥大學中藥學院

摘要(Abstract)：

潰瘍性結腸炎(ulcerative colitis,UC)為1種病因不明且易反復發作的慢性非特異性腸道疾病,由環境因素、遺傳、腸道微生物失調、粘膜和上皮屏障功能異常以及免疫失調等因素所致.其臨床癥狀主要為腹痛、腹瀉、黏液膿血便等.治療藥物主要以氨基水楊酸類、皮質類固醇、免疫抑制劑等為主,但這些藥物可能有不同的副作用,甚至嚴重的不良反應,中藥具有安全系數高、毒副作用少等優點,而起作用的主要為其有效成分.綜述概括了中藥有效成分通過6種信號通路(TLR4/MyD88/NF-κB、NLRP3、PPARγ/NF-κB、MAPK、Treg/Th17、JAK2/STAT3)治療潰瘍性結腸炎的研究進展,為中藥開發以及其對潰瘍性結腸炎的機制研究提供了新的思路.
Caused by multiple factors such as environmental factors, heredity, intestinal microbiological disorders, mucosal and epithelial barrier dysfunctions and immune disorders, ulcerative colitis(UC) is a recurrent, chronic non-specific intestinal inflammatory disease whose etiology is not very clear. UC patients have the clinical symptoms such as abdominal pain, diarrhea, tenesmus, mucus, pus and blood in the stool, etc. The main therapeutic drugs are the aminosalicylic acid, corticosteroids, immunosuppressive agents, etc. However, these drugs may have different side effects and even serious adverse reactions. Traditional Chinese medicine has long been used in treating UC with the advantages of a higher safety level and less side effects. Therefore, this review summarizes the research progress of traditional Chinese medicine on UC through six main signaling pathways(TLR4/MyD88/NF-κB, NLRP3, PPARγ/NF-κB, MAPK, Treg/Th17, JAK2/STAT3) in order to provide new ideas for the development of traditional Chinese medicine and clarify its mechanism on ulcerative colitis.

關鍵詞(KeyWords)： 潰瘍性結腸炎;中藥有效成分;信號通路
ulcerative colitis;active constituents of traditional Chinese medicine;signaling pathway

Abstract:

Keywords:

基金項目(Foundation): 國家自然科學基金(81960777,81660717,31760100,81760745);; 云南省應用基礎研究項目(2019FF002(-005),2017FB133);; 云南省教育廳科學研究基金(2019Y0332)

作者(Author): 李婷;鄒秋萍;何紅平;王亭;黃豐;李艷平;
LI Ting;ZOU Qiu-ping;HE Hong-ping;WANG Ting;HUANG Feng;LI Yan-ping;School of Chinese Medicine, Yunnan University of Traditional Chinese Medicine;

Email:

DOI:

參考文獻(References)：

• [1] 柳汝明,吳斌,趙雨晉,等.美沙拉嗪與柳氮磺胺吡啶比較治療潰瘍性結腸炎療效與安全性的系統評價[J].中國循證醫學雜志,2011,11(2):181-186.
• [2] 徐聞達.潰瘍性結腸炎的藥物治療研究進展[J].中國新通信,2019,21(4):224-225.
• [3] TABA T V S,TAHER M,EBRAHIMI D N.Update on the management of ulcerative colitis[J].Acta Med Iran,2012,50(6):363-372.
• [4] 張旭東,劉宏巖,等.烏梅丸對潰瘍性結腸炎大鼠TLRs/NF-κB/myD88信號通路影響的研究進展[J].吉林中醫藥,2019,39(3):410-413.
• [5] LIN S,LI Y,SHEN L,et al.The anti-inflammatory effect and intestinal barrier protection of HU210 differentially depend on TLR4 signaling in dextran sulfate sodium-induced murine colitis[J].DIGEST DIS SCI,2017,62(2):372-386.
• [6] XU X P,ZHANG L,LIU Z H,et al.Therapeutic efficacy of the traditional chinese medicine baishaoqiwu on TNBSinduced colitis is associated with down-regulation of the TLR4/MyD88/NF-κB signaling pathway[J].Vivo,2016,30(3):181-186.
• [7] 焦艷芳.基于TLR4/MyD88/NF-κB通路研究N-甲基野靛堿對小鼠潰瘍性結腸炎的作用[D].銀川:寧夏醫科大學,2018.
• [8] 危蓉,李佩容,張德奎,等.二氫楊梅素對小鼠葡聚糖硫酸鈉結腸炎的療效[J].第三軍醫大學學報,2017,39(2):169-174.
• [9] SUTTERWALA F S,HAASKEN S,CASSEL S L.Mechanism of NLRP3 inflammasome activation[J].Ann N Y Acad Sci,2014,1319(1):82-95.
• [10] BAUERNFEIND F G,HORVATH G,STUTZ A,et al.Cutting edge:NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression[J].J Immunol,2009,183(2):787-791.
• [11] VANAJA S K,RATHINAM V A K,FITZGERALD K A.Mechanisms of inflammasome activation:recent advances and novel insights[J].Trends Cell Biol,2015,25(5):308-315.
• [12] 付書彬,徐廣,肖小河,等.甘草查爾酮A對NLRP3炎癥小體的調控作用及機制初探[J].藥學學報,2018,53(12):2050-2056.
• [13] 杜惜惜,龔自珍,吳瑾.姜黃素抑制DSS誘導的小鼠腸上皮細胞NLRP3炎性小體活化及IL-1β分泌[J].東南大學學報(醫學版),2019,38(3):418-423.
• [14] MAI C T,WU M M,WANG C L,et al.Palmatine attenuated dextran sulfate sodium (DSS)-induced colitis via promoting mitophagy-mediated NLRP3 inflammasome inactivation[J].Mol Immunol,2019,105:76-85.
• [15] 鄒凱等.黃酮類藥物對巨噬細胞中NLRP3信號通路的調控及緩解DSS誘導的小鼠結腸炎機制的研究.[D].內蒙古,內蒙古農業大學,2018.
• [16] ADACHI M,KUROTANI R,MORIMURA K,et al.Peroxisome proliferator activatedreceptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease[J].Gut,2006,55(8):1104-1113.
• [17] PARK J H,PEYRIN-BIROULET L,EISENHUT M,et al.IBD immunopathogenesis:A comprehensive review of inflammatory molecules[J].Autoimmun Rev,2017,16(4):416-426.
• [18] 胡玲波,孫國根,鄒毅.硒和硒蛋白在炎性腸病中的作用[J].世界最新醫學信息文摘,2018,18(97):33-34.
• [19] SANDBORN W J.Oral 5-ASA therapy in ulcerative colitis:what are the implications of the new Formulations?[J].J Clin Gastroenterol,2008,42(4):338-344.
• [20] 熊興軍,李小妹,鄒坤,等.木瓜總三萜對DSS誘導潰瘍性結腸炎小鼠PPARγ/SIRT1/NF-κBp65信號通路及黏膜屏障的影響[J].中國中藥雜志,2018,43(21):4295-4304.
• [21] TIAN X L,PENG Z L,FAN H Y,et al.Aesculin protects against DSS-Induced colitis though activating PPARγ and inhibiting NF-кB pathway[J].Eur J Pharmacol,2019,857:1724-1753.
• [22] 何相宜,陳維雄,鄭重,等.川芎嗪對潰瘍性結腸炎腸粘膜過氧化物酶體增殖物激活受體γ及核因子κB的影響[J].中國臨床醫學,2008(3):341-343.
• [23] 顧怡康,王藝宙,王慧.白藜蘆醇治療潰瘍性結腸炎的機制研究進展[J].藥物生物技術,2017,24(1):72-75.
• [24] 莊秋宇,劉俊,韓家淮.p38絲裂原活化蛋白激酶的功能與調控機制[J].中國細胞生物學學報,2013,35(2):15-25.
• [25] FILOMENI G,PICCIRILLO S,ROTILIO G,et al.P38(MAPK) and ERK 1/2 dictate cell death/survival response to different pro-oxidant stimuli via p53 and Nrf2 in neuroblastoma cells SH-SY5Y[J].Biochem Pharmacol,2012,83(10):1349-1357.
• [26] 陳英,馮淬靈,李根茂,等.清金化痰湯對慢性阻塞性肺疾病氣道黏液高分泌模型大鼠表皮生長因子受體/MAPK信號通路的影響[J].中國中醫藥信息雜志,2016,23(10):56-62.
• [27] LI C P,LI J H,HE S Y,et al.Effect of curcumin on p38MAPK expression in DSS-induced murine ulcerative colitis[J].Genet Mol Res,2015,14(2):3450-3458.
• [28] KANAJI N,NELSON A,ALLEN-GIPSON D S,et al.The p38 mitogen activated protein kinases modulate endothelial cell survival and tissue repair[J].Inflamm Res,2012,61(3):233-244.
• [29] 何雙艷,李玨宏,石蕾,等.姜黃素對DSS誘導的潰瘍性結腸炎小鼠p38MAPK表達的影響[J].實用醫學雜志,2014,30(4):539-541.
• [30] 萬志華,蔡艷,郭興,等.RAS/MAPK/NF-κB信號通路在姜黃素治療大鼠結腸癌中的作用[J].中國現代普通外科進展,2018,21(11):845-849.
• [31] 王娟.苦參堿衍生物M19對小鼠實驗性結腸炎的防治作用及機制研究[D].上海,第二軍醫大學,2013.
• [32] 沈鵬.吳茱萸湯及吳茱萸堿對IBD模型小鼠的保護作用及機制研究[D].遼寧,吉林大學,2019.
• [33] LIU B H,LI S D,SUI X D,et al.Root Extract of Polygonum cuspidatum Siebold & Zucc.Ameliorates DSS-Induced Ulcerative Colitis by Affecting NF-kappaB Signaling Pathway in a Mouse Model via Synergistic Effects of Polydatin,Resveratrol,and Emodin[J].Front pharmacol,2018,9:347-360.
• [34] PARK J S,OH Y,PARK O,et al.PEGylated TRAIL ameliorates experimental inflammatory arthritis by regulation of Th17 cells and regulatory T cells[J].J Control Release.2017,267:163-171.
• [35] XU M,ZUO D,LIU X,et al.MiR-155 contributes to Th17 cells differentiation in dextran sulfate sodium (DSS)-induced colitis mice via Jarid2[J].Biochem Bioph Res Co,2017,488(1):6-14.
• [36] 李思慧,吳巧鳳.腸道菌群對Th17/Treg免疫平衡和炎癥性腸病影響的研究進展[J].免疫學雜志,2019,35(8):722-726.
• [37] RUBTSOVY P,RASMUSSEN J P,RUDENSKY A Y,et al.Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces[J].Immunity,2008,28(4):546-558.
• [38] 王寧,金敬一,陳麗華.免疫分子對CD4 + Treg的調節作用[J].免疫學雜志,2018,34(1):73-79.
• [39] HAQUE M,FINO K,LEI F,et al.Utilizing regulatory T cells against rheumatoid arthritis[J].Front Oncol,2014,4:209-228.
• [40] WEI C B,TAO K,JIANG R,et al.Quercetin protects mouse liver against triptolide- induced hepatic injury by restoring Th17/Treg balance through Tim-3 and TLR4-MyD88-NF-κB pathway[J].Int Immunopharmacol,2017,53:73-82.
• [41] 唐慶,范恒,劉星星,等.小檗堿對結腸炎小鼠Th17/Treg細胞分化及IL-35的影響[J].現代中西醫結合雜志,2019,28(1):1-5.
• [42] CUI H T,CAI Y Z,JIA B T,et al.Berberine regulates Treg/Th17 balance to treat ulcerative colitis through modulating the gut microbiota in the colon[J].Front Pharmacol,2018,9:1-17.
• [43] 張靜,付妤,錢偉,等.雷公藤甲素對小鼠實驗性結腸炎Th17/Treg的調節作用[J].胃腸病學和肝病學雜志,2011,20(12):1118-1121.
• [44] 郭艷,孫春鋒,雷家才,等.黃芪多糖對實驗性潰瘍性結腸炎大鼠Th17相關細胞因子的影響[J].中華中醫藥學刊,2013,31(6):1375-1377.
• [45] ZHAO H M,WANG Y,HUANG X Y,et al.Astragalus polysaccharide attenuates rat experimental colitis by inducing regulatory T cells in intestinal Peyer's patches[J].World J Gastroentero,2016,22(11):3175-3185.
• [46] 王佐,吳正祥,吳強,等.白芍總甙對大鼠實驗性結腸炎Th17細胞相關因子的作用[J].世界華人消化雜志,2010,18(1):84-88.
• [47] GUTHRIE G J K,ROXBURGH C S D,RICHARDS C H,et al.Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer[J].Brit J Cancer,2013,109(1):131–137.
• [48] XU Y Y,GUO M,ZHOU F,et al.Regulation of CD44v6 expression in gastric carcinoma by theIL‐6/STAT3 signaling pathway and its clinical significance[J].Oncotarget,2017,8(28):45848–45861.
• [49] FU L,WEI L W,ZHAO M D,et al.Investigation of JAKs-STAT 3 in lipopolysaccharide-induced intestinal epithelial cells[J].Clin Exp Immunol,2016,186(1):75-85.
• [50] 毛婧,朱瑩,陳程,等.潰結寧膏穴位敷貼對實驗性潰瘍性結腸炎大鼠IL-6/JAK2/STAT3信號通路的影響[J].中國中醫急癥,2018,27(7):1167-1170.
• [51] 席進,葛思堂,解巧麗,等.綠茶多酚抑制腸道JAK2/STAT3信號通路保護三硝基苯磺酸誘導的小鼠結腸炎腸黏膜屏障[J].細胞與分子免疫學雜志,2018,34(3):237-241.
• [52] 步楠,王燁,范彥秋,等.雷公藤多苷通過JAK2/STAT3信號通路減輕潰瘍性結腸炎大鼠腸黏膜細胞凋亡及炎癥的實驗研究[J].現代消化及介入診療,2019,24(5):466-470.
• [53] 譚悅,關雅迪,鄭長清.山姜素對葡聚糖硫酸鈉誘導的潰瘍性結腸炎小鼠的保護作用及其作用機制研究[J].現代藥物與臨床,2018,33(6):1303-1311.
• [54] 王倩,范文濤.馬齒莧多糖對潰瘍性結腸炎相關性結腸IL-6/STAT3信號通路的影響[J].世界中醫藥,2013,8(10):1256-1260.